Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486

被引:133
作者
Liu, Z
Auboeuf, D
Wong, JM
Chen, JD
Tsai, SY
Tsai, MJ
O'Malley, BW
机构
[1] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[2] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01655 USA
关键词
D O I
10.1073/pnas.122225699
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Selective receptor modulators, such as the antiprogestin RU486, are known to exhibit partial agonist activities in a cell-type-dependent manner. Employing an in vitro chromatin transcription system that recapitulates progesterone receptor (PR)-mediated transcription in vivo, we have investigated the molecular basis by which the antiprogestin RU486 regulates transcription in a cell-type-specific manner. We have compared the effects of RU486 on PR-dependent transcription in vitro using T47D and HeLa cell nuclear extracts. RU486 exhibits a differential ability to activate transcription within these two cell types. The differential effect on transcription correlates with different ratios of endogenous coactivators/corepressors in these cells. Unlike agonist-bound PR that interacts only with coactivators such as steroid receptor coactivator-1 (SRC-1), RU486-bound PR binds to both coactivator SRC-1 and corepressor silencing mediator for retinold and thyroid hormone receptor (SMRT) in vitro. Both SRC-1 and SMRT have the capacity to modulate RU486-dependent activity. Moreover, a change in the relative levels of SRC-1 and SMRT contained in our chromatin transcription system modulates agonist/antagonist effects of RU486 on transcription by PR. Our data indicate that the ability of RU486 to activate transcription is modulated by the ratio of coactivators to corepressors and substantiate the important roles of coregulators in the regulation of steroid receptor mediated transactivation in response to selective receptor modulators.
引用
收藏
页码:7940 / 7944
页数:5
相关论文
共 34 条
[11]  
Glass CK, 2000, GENE DEV, V14, P121
[12]   LIGAND-INDEPENDENT REPRESSION BY THE THYROID-HORMONE RECEPTOR-MEDIATED BY A NUCLEAR RECEPTOR CO-REPRESSOR [J].
HORLEIN, AJ ;
NAAR, AM ;
HEINZEL, T ;
TORCHIA, J ;
GLOSS, B ;
KUROKAWA, R ;
RYAN, A ;
KAMEL, Y ;
SODERSTROM, M ;
GLASS, CK ;
ROSENFELD, MG .
NATURE, 1995, 377 (6548) :397-404
[13]   THE MOLECULAR-BIOLOGY OF RU486 - IS THERE A ROLE FOR ANTIPROGESTINS IN THE TREATMENT OF BREAST-CANCER [J].
HORWITZ, KB .
ENDOCRINE REVIEWS, 1992, 13 (02) :146-163
[14]  
ING NH, 1992, J BIOL CHEM, V267, P17617
[15]   The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT [J].
Jackson, TA ;
Richer, JK ;
Bain, DL ;
Takimoto, GS ;
Tung, L ;
Horwitz, KB .
MOLECULAR ENDOCRINOLOGY, 1997, 11 (06) :693-705
[16]   Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones [J].
Katzenellenbogen, JA ;
OMalley, BW ;
Katzenellenbogen, BS .
MOLECULAR ENDOCRINOLOGY, 1996, 10 (02) :119-131
[17]   2 TYPES OF ANTIPROGESTINS IDENTIFIED BY THEIR DIFFERENTIAL ACTION IN TRANSCRIPTIONALLY ACTIVE EXTRACTS FROM T47D CELLS [J].
KLEINHITPASS, L ;
CATO, ACB ;
HENDERSON, D ;
RYFFEL, GU .
NUCLEIC ACIDS RESEARCH, 1991, 19 (06) :1227-1234
[18]   Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and receptor-dependent cell-free transcription of chromatin [J].
Liu, Z ;
Wong, JM ;
Tsai, SY ;
Tsai, MJ ;
O'Malley, BW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) :9485-9490
[19]   THE NUCLEAR RECEPTOR SUPERFAMILY - THE 2ND DECADE [J].
MANGELSDORF, DJ ;
THUMMEL, C ;
BEATO, M ;
HERRLICH, P ;
SCHUTZ, G ;
UMESONO, K ;
BLUMBERG, B ;
KASTNER, P ;
MARK, M ;
CHAMBON, P ;
EVANS, RM .
CELL, 1995, 83 (06) :835-839
[20]   Nuclear receptor coregulators: Cellular and molecular biology [J].
McKenna, NJ ;
Lanz, RB ;
O'Malley, BW .
ENDOCRINE REVIEWS, 1999, 20 (03) :321-344